Skip to main content
. Author manuscript; available in PMC: 2014 Jan 18.
Published in final edited form as: Laryngoscope. 2011 Oct 13;122(1):95–102. doi: 10.1002/lary.22345

Fig. 2.

Fig. 2

Recombinant human bone morphogenetic protein-2 (rhBMP-2) in vivo treatment effects on survival. (A) Kaplan-Meier survival curve for animals injected orthotopically with UMSCC-14A cells pretreated with rhBMP-2 or control. Animals injected with rhBMP-2–treated cells had worse survival secondary to rapid local tumor growth (P = .0012). (B) Data summarized for two representative human oral cancer cell lines showing statistically significant worse survival in the animals orthotopically injected with rhBMP-2–treated cells.